Severe Asthma.

Slides:



Advertisements
Similar presentations
Treatments for Asthma Ghazaleh Ebrahimnejadalamaki, Gea Panić, Natali Surkic, Romina Isip [1] PHM142 Fall 2015 Coordinator: Dr. Jeffrey Henderson Instructor:
Advertisements

Biologics in Asthma—The Next Step Toward Personalized Treatment
Precision medicine in patients with allergic diseases: Airway diseases and atopic dermatitis—PRACTALL document of the European Academy of Allergy and.
NEW TREATMENT OPTIONS IN ASTHMA
Fig. 1. Pathological mechanisms of asthma
Moderate-to-Severe Asthma Management
Anti-IgE effect of the mAb omalizumab
Clinical Trials in IBD.
Evolution of Treatment Strategies Targeting IL-23 for Psoriasis
Why Gene Therapy for Hemophilia?
Diagnosis, Evaluation, and Therapy for Severe Refractory Eosinophilic Asthma.
Allergy Testing in Children
Chronic Rhinosinusitis
Clinical Review.
Stepping Up Asthma Control for Effective Management
Atopic Dermatitis Treatment Landscape
Adapted from Catley et al, Pharm Therap 2011
Induction Chemotherapy for Patients With High-Risk or Secondary AML
Chronic Idiopathic Urticaria
Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma
Addressing Disease Burden in Asthma
Asthma and Atopic Comorbidities
Postpartum Depression
Next-Gen Psoriasis Therapies:
Case Studies in Unresectable Hepatocellular Carcinoma
Gene Therapy: Past, Present, and Future
Emerging Atopic Dermatitis Treatments:
Essential Concepts in the Use of Immunotherapies in Bladder Cancer
Ask the Experts.
Current application of exhaled nitric oxide in clinical practice
Perspectives on the Impact of Inflammation in OA
Advancing the Treatment of IBD With Biologics
When Is Biologic Therapy Appropriate for HS?
Improving Outcomes in Psoriatic Arthritis
The Evolving Treatment Landscape in Atopic Dermatitis
Oral Prostanoids and PAH
Background. Advancing the Care of Patients With Moderate to Severe Atopic Dermatitis: A Case-Based Discussion.
Advancing Patient Care in RA
Advances in Severe Asthma Management
Guide to Atopic Dermatitis
Challenges in Severe Asthma
Precision medicine in patients with allergic diseases: Airway diseases and atopic dermatitis—PRACTALL document of the European Academy of Allergy and.
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Understanding the Updated Guidelines for ALK Testing in NSCLC
EGPA.
Anti–IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison  William Busse, MD, Geoffrey Chupp,
Achieving Asthma Control
Patient Questions and Expert Answers in Psoriasis:
Daniel L. Hamilos, MD  Journal of Allergy and Clinical Immunology 
Severe Asthma and Comorbidities
Optimizing Joint Health in Hemophilia
Diagnosis, Evaluation, and Therapy for Severe Refractory Eosinophilic Asthma.
Update on the Management of Atopic Dermatitis
Anti-interleukin 13 for asthma: stick or twist?
Novel Concepts in the Management of RCC
Biologics and biomarkers for asthma, urticaria, and nasal polyposis
From Adjuvant to Metastatic in Melanoma
This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.
HAE Prophylaxis.
Checkpoint Inhibitors in First-Line Advanced NSCLC
Peanut Allergy Immunotherapy
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Pathophysiologic Targets of Allergic Asthma
GINA Pocket Guide Difficult to treat and severe asthma in adults and adolescents V2.0 April 2019 This slide set is restricted for academic and educational.
Updates in Progressive MS
Albert Y. Wu, MD, Sanjiv Sur, MD, J. Andrew Grant, MD 
The Asthma Treatment Gap
Exploring the Role of Biologics in Reducing Oral Corticosteroid Use in Severe Asthma.
Foundations of Asthma.
Foundations of Asthma.
Presentation transcript:

Severe Asthma

This program will include a discussion of investigational agents not approved by the FDA for use in the US.

Severe Asthma: Overview

How Is Severe Asthma Defined? ERS/ATS Guidelines

How Is Uncontrolled Asthma Defined? ERS/ATS Guidelines

How Is Severe Asthma Defined? GINA Guidelines

Evolution of Asthma Classification

T2-Mediated Inflammation

Non-T2-Mediated Inflammation

Asthma Phenotypes

Severe Asthma Phenotyping

Proposed Asthma Phenotypes

Asthma Endotypes

Selected Asthma Endotypes

Potential Application of Asthma Biomarkers

Ideal Biomarker Characteristics

Severe Asthma Biomarkers

Biologics for Severe Asthma

Blocking the IgE Allergic Cascade

Omalizumab

Anti-IL-5 Therapy in Eosinophilic Asthma

Mepolizumab

Mepolizumab Phase 3 Study Results

Reslizumab

Reslizumab Phase 3 Study Results

Benralizumab

Benralizumab Phase 3 Study Results

Anti-IL-4/IL-13 Therapy

Inhibiting IL-13 in Severe Asthma

Dupilumab Phase 2b Study

Dupilumab Phase 3 Study

Moving Toward Precision Medicine in Severe Asthma

Abbreviations

Abbreviations (cont)